Chemotherapy-Induced Neutropenia Treatment Market Size 2034
Chemotherapy-Induced Neutropenia Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: HLCA25303 | Pages: 1 - 243 | Formats*: |
| Category : Healthcare | |||
Chemotherapy-Induced Neutropenia Treatment Market Introduction and Overview
According to SPER Market Research, the Global Chemotherapy-Induced Neutropenia Treatment Market is estimated to reach USD 895.55 million by 2034 with a CAGR of 3.96%.
The report includes an in-depth analysis of the Global Chemotherapy-Induced Neutropenia Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The Chemotherapy-Induced Neutropenia Treatment Market was valued at USD 607.33 million in 2024 and is projected to grow at a CAGR of 3.96% from 2025 to 2034. This growth can be attributed to ongoing advancements in treatment options, an increasing use of chemotherapy, and rising healthcare expenditures in developing nations, among other factors. Additionally, the global rise in cancer prevalence significantly drives the chemotherapy-induced neutropenia (CIN) treatment market.
By Treatment Type Insights:
The market is divided by treatment type into granulocyte colony-stimulating factor (G-CSF) therapy, antibiotics, granulocyte transfusion, antifungals, and other treatments. G-CSF therapy led the market in 2024, as it effectively prevents and manages neutropenia, a common side effect of chemotherapy where neutrophil count decreases. By promoting neutrophil production, it helps lower the risk of severe neutropenia and related complications, such as infections and treatment delays. This therapy improves patient comfort, satisfaction, and treatment results, contributing to growth in the G-CSF segment.
By Drug Type Insights:
The chemotherapy-induced neutropenia (CIN) treatment market is divided into branded drugs and biosimilars. In 2024, branded drugs led the market due to their thorough clinical trials that prove their effectiveness and safety. Healthcare providers and patients trust these branded drugs more because of their established profiles. This trust increases their demand in the CIN market. Branded drugs also benefit from patent protection, which allows companies exclusive rights to sell them for about 20 years, preventing generic versions from entering the market and enabling higher prices, thus supporting further growth in this segment.
By Route of Administration Insights:
The chemotherapy-induced neutropenia treatment market is divided into parenteral and oral segments, with parenteral therapies leading in 2024. These injectable medications, such as filgrastim and pegfilgrastim, effectively boost neutrophil production in the bone marrow, quickly increasing neutrophil counts. This rapid action helps manage neutropenia and prevent complications, including severe infections that may lead to hospitalization and treatment delays. By raising neutrophil levels, parenteral therapies enhance patient safety, adherence to treatment, and overall treatment effectiveness.
By Distribution Channel Insights:
The chemotherapy-induced neutropenia treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In 2024, hospital pharmacies led the market due to their role in centralizing medication distribution, particularly for chemotherapy drugs. They provide timely access to treatments and offer comprehensive services like dose calculation, drug dispensing, and medication counseling. Pharmacists work with healthcare teams to improve treatment effectiveness and monitor patient safety, which is expected to drive growth in this segment.
Regional Insights:
In 2024, North America led the chemotherapy-induced neutropenia treatment market. The region experiences a relatively high incidence of cancer, with millions of new cases diagnosed annually. Chemotherapy is a prevalent treatment method for various cancers, which contributes to the incidence of CIN in this area. The extensive use of chemotherapy fuels the demand for CIN treatments in North America. Moreover, the region is equipped with advanced healthcare infrastructure, including well-equipped hospitals, specialized cancer centers, and research institutions. The availability of cutting-edge facilities and expertise in oncology enhances the diagnosis, treatment, and management of CIN, thereby increasing market demand for innovative therapies and supportive care interventions.
Market Competitive Landscape:
The market includes a variety of therapeutic interventions designed to prevent and manage neutropenia, a frequent complication of chemotherapy. It is characterized by established pharmaceutical companies that provide innovative treatment options and biosimilar alternatives, alongside a growing emphasis on personalized medicine and targeted therapies. With advancements in oncology research and improved patient access to care, the CIN treatment market continues to develop, addressing the diverse needs of patients undergoing chemotherapy globally.
Recent Developments:
In February 2024, Coherus BioSciences, Inc. successfully introduced UDENYCA ONBODY, the company's on-body injector (OBI) version of UDENYCA (pegfilgrastim-cbqv). The launch is progressing effectively, with nationwide distribution and robust acceptance by healthcare providers.
In March 2023, Coherus BioSciences received approval from the U.S. FDA for Udencya, a biosimilar version of pegfilgrastim utilized in the treatment of febrile neutropenia caused by chemotherapy.
In November 2023, Evive Biotech (Evive) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ryzneuta (Efbemalenograstim alfa), a distinctive long-acting Granulocyte colony-stimulating factor (G-CSF) designed to decrease the incidence of infection, as indicated by febrile neutropenia, in adult patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer therapies associated with a clinically significant occurrence of febrile neutropenia.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, Evive Biotech, Kyowa Kirin Co., Ltd, Novartis AG, Pfizer Inc, Sanofi. |
- Global Chemotherapy-Induced Neutropenia Treatment Market Size (FY 2021-FY 2034)
- Overview of Global Chemotherapy-Induced Neutropenia Treatment Market
- Segmentation of Global Chemotherapy-Induced Neutropenia Treatment Market By Treatment Type (Granulocyte colony-stimulating factor therapy, Antibiotics, Granulocyte transfusion, Antifungals, Other treatment type)
- Segmentation of Global Chemotherapy-Induced Neutropenia Treatment Market By Drug Type (Branded, Biosimilars)
- Segmentation of Global Chemotherapy-Induced Neutropenia Treatment Market By Route of administration (Parenteral, Oral)
- Segmentation of Global Chemotherapy-Induced Neutropenia Treatment Market By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies)
- Statistical Snap of Global Chemotherapy-Induced Neutropenia Treatment Market
- Expansion Analysis of Global Chemotherapy-Induced Neutropenia Treatment Market
- Problems and Obstacles in Global Chemotherapy-Induced Neutropenia Treatment Market
- Competitive Landscape in the Global Chemotherapy-Induced Neutropenia Treatment Market
- Details on Current Investment in Global Chemotherapy-Induced Neutropenia Treatment Market
- Competitive Analysis of Global Chemotherapy-Induced Neutropenia Treatment Market
- Prominent Players in the Global Chemotherapy-Induced Neutropenia Treatment Market
- SWOT Analysis of Global Chemotherapy-Induced Neutropenia Treatment Market
- Global Chemotherapy-Induced Neutropenia Treatment Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Chemotherapy-Induced Neutropenia Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chemotherapy-Induced Neutropenia Treatment Market
7. Global Chemotherapy-Induced Neutropenia Treatment Market, By Treatment Type (USD Million) 2021-2034
- 7.1. Granulocyte colony-stimulating factor therapy
- 7.2. Antibiotics
- 7.3. Granulocyte transfusion
- 7.4. Antifungals
- 7.5. Other treatment type
8. Global Chemotherapy-Induced Neutropenia Treatment Market, By Drug Type (USD Million) 2021-2034
- 8.1. Branded
- 8.2. Biosimilars
9. Global Chemotherapy-Induced Neutropenia Treatment Market, By Route of Administration (USD Million) 2021-2034
- 9.1. Parenteral
- 9.2. Oral
10. Global Chemotherapy-Induced Neutropenia Treatment Market, By Distribution Channel (USD Million) 2021-2034
- 10.1. Hospital pharmacies
- 10.2. Retail pharmacies
- 10.3. Online pharmacies
11. Global Chemotherapy-Induced Neutropenia Treatment Market, (USD Million) 2021-2034
- 13.1. Global Chemotherapy-Induced Neutropenia Treatment Market Size and Market Share
12. Global Chemotherapy-Induced Neutropenia Treatment Market, By Region, (USD Million) 2021-2034
- 12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
- 12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
- 12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
- 12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
- 12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America
13. Company Profile
- 13.1. Amgen Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. BeyondSpring Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Biocon Biologics Inc
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Cellerant Therapeutics
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Coherus BioSciences, Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Evive Biotech
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Kyowa Kirin Co., Ltd
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Novartis AG
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Pfizer Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Sanofi
- 15.10.1. Company details
- 15.10.2. Financial outlook
- 15.10.3 Product summary
- 15.10.4. Recent developments
- 13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Chemotherapy-Induced Neutropenia Treatment Market is projected to reach USD 895.55 million by 2034, growing at a CAGR of of 3.96% during the forecast period.
Chemotherapy-Induced Neutropenia Treatment Market grew in Market size from 2025. The Market is expected to reach USD 895.55 million by 2034, at a CAGR of 3.96 billion% during the forecast period.
Chemotherapy-Induced Neutropenia Treatment Market CAGR of 3.96% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Chemotherapy-Induced Neutropenia Treatment Market size is USD 895.55 million from 2025 to 2034.
Chemotherapy-Induced Neutropenia Treatment Market is covered By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Chemotherapy-Induced Neutropenia Treatment Market.
Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, Evive Biotech, Kyowa Kirin Co., Ltd, Novartis AG, Pfizer Inc, Sanofi.
The report includes an in-depth analysis of the Global Chemotherapy-Induced Neutropenia Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
